

T

Your ref: New

Our ref: 2023/278/ILM/IGGH/PNG

Dear NCB colleagues,

In the context of Operation Pangea, INTERPOL Illicit Goods and Global Health (IGGH) would like to alert all member countries regarding an emerging trend of **counterfeit Ozempic injection pens**. This is a follow up from the alert message (attached) sent in September 2022.

The products are Apridra Solostar pens containing insulin glulisine which are relabelled as Ozempic pens. There was an incident where a patient with Type 2 Diabetes injected herself with the counterfeit pen for three weeks and was hospitalised.

Please refer to the photos below showing how the pens are different and the actual photo of a counterfeit injection pen purchased in Pakistan.

The white dial on the Apridra Solostar pen is further to be back of the pen as compared to the Ozempic one.

These counterfeit pens are found in the Middle East, Russia, Azerbaijan, Egypt, Iraq, Jordan, Lebanon, Russia, Turkey and Uzbekistan. These products have been sold both within the legal and illegal supply chain.



Photo 1: Apridra Solostar pen




Photo 2: Ozempic injection pen






Photo 3: Actual image of the counterfeit Ozempic Injection Pen product bought in Pakistan

We strongly recommend that you circulate this message to your country's law enforcement bodies to alert them about this trend and to take the required preventive and precautionary measures they deem necessary. All recipients are strongly encouraged to share with INTERPOL IGGH on any data or similar cases that you have concerning this product.

Thank you.

Best regards,

— F

FROM : IPSTG
OEC/ILM/IGGH

Your ref: New
Our ref: 2022/382/ILM/IGGH/PNG

Dear NCB colleagues,

In the context of Operation Pangea, INTERPOL Illicit Goods and Global Health (IGGH) would like to alert you regarding a new trend happening in Ireland whereby the product - **Ozempic injection pens** are sold in beauty clinics to


consumers for the purpose of weight loss.

The situation is that this product is prescribed by consultants and administered to patients with Type 2 diabetes and obesity. The product is sold for €250 each by the beauty clinic owners and is injected into the stomach area of the patients.

This product causes serious health implications for people using these pens without authorised medical supervision.

This product was authorised by the European Medicines Agency for distribution in Ireland, the UK and Malta but is now being distributed outside the legal distribution chain. Clinics are also importing this product via the illegal supply chain and possibility that this product may be sold online.

Please find below the available photos of the product:



For use by one person only.

Keep out of the sight and reach of children.
Read the package leaflet before use.

Store in a refrigerator. Do not freeze.
After the first use of the pen, store below 30°C. Do not freeze.

Keep the pen cap on in order to protect from light.
Discard pen 6 weeks after first use.
Do not store the pen with a needle attached.

Each dose (0.37 ml) contains 0.5 mg semaglutide (1.34 mg/ml),
disodium phosphate dihydrate, propylene glycol, phenol,
hydrochloric acid/sodium hydroxide
injections

Novo Nordisk A/S
Novo Allé, DK-2880 Bagsvaerd, Denmark
EU/1/17/1251/003

Ireland
United Kingdom
Malta

POM



We strongly recommend that you circulate this message to your country's law enforcement bodies to alert them about this trend so as to allow them to take whatever preventive and precautionary measures they deem necessary. All recipients are strongly encouraged to share any data or similar cases that you have concerning this product.

Thank you.

Best regards,